CDK4 and carcinoma: Several studies reported the role of nimbolide, to suppress carcinoma cells viability and slows tumor growth by inhibiting CDK4/6 activity, (which leads to RB hypo phosphorylation and cell cycle arrest), and by inhibiting PI3K-AKT, MAP kinase, and JAK-STAT pathways (which are hyper activated in many types of carcinoma) (45, 109–115).